Introduction
============

Severe aplastic anemia (SAA) is a life-threatening disorder for which allogeneic hematopoietic stem cell transplantation (HSCT) is the current available curative treatment. HSCT from a matched sibling donor (MSD) is the preferred therapy for children with acquired SAA. The outcomes of HSCT from MSDs are excellent with survival rates of 90% or higher[@B1][@B2][@B3]. In addition, some comparative studies support the superiority of MSD-HSCT over immunosuppressive therapy (IST), given the risk of clonal evolution and the high relapse rate after IST[@B4][@B5]. However, only 1 to 2 out of 10 children with SAA have a MSD. Therefore, IST is widely used as the first-line treatment for patients who lack a MSD before considering HSCT from an unrelated donor (URD)[@B6][@B7].

Recently, there has been progress in HSCT using URDs for childhood SAA. The best donor selection using molecular typing of human leukocyte antigen (HLA) played a major role, but modifications of the conditioning regimen and improvements in supportive care have also occurred. Nowadays, the survival after well-matched URD HSCT approaches the outcome of MSD transplants[@B8][@B9][@B10]. A recent randomized study showed that IST with rabbit-antithymocyte globulin (ATG) had an inferior response and survival rate compared with those of horse-ATG[@B11]. In addition, the use of IST before HSCT has been associated with lower survival[@B12][@B13]. As horse-ATG is no longer available in Korea, URD HSCT is occasionally recommended as an initial treatment for children with SAA partially because of the limited efficacy of IST using rabbit-ATG.

Given the recent data with favorable outcome, HSCT with well-matched URD has become a realistic option for pediatric patients who have no suitable related donors and who are refractory to IST[@B14]. However, it is quite challenging to treat patients with refractory SAA who lack suitable related or URDs. Of course, supportive therapy could be an option and other types of novel immunosuppressive therapies could be a possibility. In addition, alternative donor transplantations using cord blood or haploidentical family donors (HFDs) could be potential treatments for children with refractory SAA in need of frequent transfusions and repeated antibiotic therapy.

This article reviews the status of HLA-haploidentical HSCT from mismatched family donors as an alternative therapeutic approach for children and adolescents with acquired SAA.

History of HSCT from HFD
========================

HSCT is a curative procedure for a wide range of pediatric malignant and nonmalignant diseases. Unfortunately, it is not always possible to find a donor for patients requiring HSCT. Thus, a certain number of patients still could not find a donor, resulting in death without undergoing transplant. The need for alternative donors has pressed on the development of new transplantation approaches such as transplantation from HLA-haploidentical mismatched family donors. HSCT from HFDs has several advantages ([Table 1](#T1){ref-type="table"}). (1) Virtually all patients who need HSCT can find a donor. (2) Transplantation could be performed immediately, which is critical to patients with high-risk malignant diseases or very SAA requiring urgent treatment. (3) Further access to donors is easy for cellular therapy to treat relapse and infections or to undergo a second transplantation. In addition, HFDs could rescue patients experiencing early graft failure (GF), which is a life-threatening complication requiring prompt intervention after allogeneic HSCT[@B15].

Even though haploidentical HSCT seemed to be an attractive procedure with the amazing benefit of readily available donors, early attempts at haploidentical HSCT from genetically haploidentical family members were disappointing because of the development of refractory graft-versus-host disease (GVHD) and excessively high transplant-related mortality (TRM). High rates of graft rejection (GR) and refractory GVHD were major drawbacks to the use of haploidentical HSCT for patients who need transplantation but lack a suitable donor. In addition, delayed immune recovery and the high prevalence of infection are significant obstacles. Initial practice revealed that haploidentical HSCT had a considerably higher incidence of GF and GVHD, resulting in high rates of morbidity and mortality[@B16][@B17].

Recent advances in haploidentical HSCT
======================================

Recent advances in effective *ex vivo* depletion of T-cells or unmanipulated *in vivo* regulation of T-cells, better supportive care, and optimal conditioning regimens have significantly improved the outcome of haploidentical transplant. T-cell depletion (TCD) of donor grafts to prevent fatal GVHD is crucial for successful haploidentical HSCT. The methods of TCD could be carried out *in vivo* (T-cell-replete transplant) or *ex vivo* (T-cell-depleted transplant). Various approaches have been developed, including *ex vivo* selection of CD34^+^ cells with or without megadoses of purified stem cells, *ex vivo* TCD, *in vivo* TCD using T-cell antibodies such as ATG, and posttransplant cyclophosphamide (PTCY) ([Table 2](#T2){ref-type="table"}). The *ex vivo* techniques to remove T-cells have evolved from the selection of CD34^+^ hematopoietic stem cell progenitors towards the depletion of CD3^+^ cells and more recently the depletion of αβ^+^ T-cells. Compared with the positive selection of CD34^+^ cells, direct depletion of CD3^+^ cells has the advantage of increased numbers of natural killer cells, monocytes, and other immunomodulating cells[@B18]. The depletion of CD3^+^ cells is superior to the selection of CD34^+^ cells in terms of rapid engraftment and immune reconstitution[@B19][@B20]. Moreover, preliminary reports on the new method of αβ^+^ TCD further showed improved outcomes of T-cell-depleted haploidentical transplants. The depletion of αβ^+^ T-cells produces grafts containing many γδ^+^ lymphocytes and other effector cells. While αβ^+^ T-cells are known to be associated with the initiation of GVHD, γδ^+^ T-cells can enhance immune reconstitution and are not implicated in GVHD[@B21]. Bertaina et al.[@B22] reported the promising results of αβ^+^ T-cell-depleted haploidentical HSCT for pediatric patients with nonmalignant diseases, with a TRM and an overall survival rate of 9.3% and 91.1%, respectively.

Besides T-cell-depleted haploidentical HSCT, there have also been remarkable advances in unmanipulated T-cell-replete transplant. Huang et al.[@B23] reported the results of T-cell-replete haploidentical transplant using an intensive preparative regimen containing high doses of ATG. In addition, recent approaches have been developed using PTCY to control GVHD by eliminating allo-activated donor T-cells[@B24]. Remarkable advances in haploidentical transplants have enabled successful T-cell-depleted and T-cell-replete transplantation[@B23][@B24][@B25].

Recently, we reported on haploidentical HSCT using *ex vivo* CD3-depleted grafts in children and adolescents[@B26]. Twenty-eight pediatric patients underwent T-cell-depleted haploidentical HSCT; 10 had malignant diseases and 18 had nonmalignant hematologic diseases including 16 with acquired SAA. Twenty-six patients achieved neutrophil engraftment at a median of 11 days (range, 9 to 15 days). The cumulative incidences of severe grades III-IV acute GVHD and extensive chronic GVHD were 14% and 11%, respectively. Four patients died of non-relapse-related causes (two from cytomegalovirus infection, one from encephalopathy, and one from autoimmune hemolytic anemia) and one of leukemia relapse. The TRM at 100 days, 1 year, and 2 years were 0.0%, 10.7%, and 14.3%, respectively. The overall survival rate of all patients was 82.1% and those for nonmalignant diseases and malignant diseases were 94.4% and 60.0%, respectively ([Fig. 1](#F1){ref-type="fig"}).

Currently, given the low TRM and acceptable occurrence of GVHD, haploidentical HSCT is considered as an established option for children and adults who have diseases curable by HSCT but lack suitable related or URDs.

HSCT from HFD for patients with acquired SAA
============================================

Historically, the haploidentical HSCT for patients with SAA was invariably unsuccessful, with high rates of GF and opportunistic infection. Some studies of CD34-selected haploidentical HSCT reported encouraging outcomes, but the number of patients was too small to justify a greater use of this approach[@B27][@B28]. Although haploidentical HSCT is considered an established option for both children and adults with malignant diseases, only a few reports have addressed the use of haploidentical transplant in children with acquired aplastic anemia[@B28][@B29][@B30][@B31]. A review by the EBMT SAA Working Party on unmanipulated haploidentical HSCT for 20 patients with acquired SAA revealed a poor outcome with an overall survival rate of 30%[@B32].

Recently, the situation has changed considerably. Several notable reports in recent years have supported haploidentical transplant as a viable option for the treatment of acquired SAA[@B33][@B34][@B35][@B36][@B37][@B38]. The details of the studies are summarized in [Table 3](#T3){ref-type="table"}.

Three studies of transplants without *ex vivo* TCD reported survival rates of 65% to 85%[@B33][@B35][@B36]. Two of these three studies used unmanipulated peripheral blood stem cells after non-total-body-irradiation (TBI) conditioning with ATG at a dose of 10 mg/kg of recipient weight[@B33][@B35]. The remaining study of 17 children and adolescents with refractory SAA employed a distinctive approach using peripheral blood and G-CSF-primed bone marrow stem cells with additional mesenchymal stem cells derived from an URD and basiliximab to further reduce GVHD[@B36]. Severe III-IV acute GVHD only occurred in one patient.

A study evaluated haploidentical HSCT with *ex vivo* TCD in 12 pediatric patients. All 12 patients survived and were transfusion-independent at a median follow-up of 14.3 months[@B34]. A report on haploidentical HSCT using reduced-intensity conditioning (RIC) with high-dose PTCY showed that six of eight patients with refractory SAA survived with full donor chimerism[@B37]. Another recent study using the same approach with RIC and PTCY reported overall survival rates of 67.1% in 16 patients with SAA[@B38].

These recent emerging evidences for haploidentical HSCT in SAA has provided additional therapeutic options to consider in patients who experience refractory diseases but do not have a suitable related or URD.

Update of our experience with haploidentical HSCT for children and adolescents with acquired SAA (unpublished data)
===================================================================================================================

We have published our preliminary experience with T-cell-depleted haploidentical transplant for 12 patients with acquired SAA[@B34]. Up until February 2015, 21 patients with acquired SAA received haploidentical transplants using *ex vivo* T-cell-depleted grafts at our center. Sixteen patients received CD3-depleted grafts and five received αβ-depleted stem cells. Conditioning regimens consisted of fludarabine (FLU), cyclophosphamide (CY), and r-ATG with or without low-dose total body irradiation (LD-TBI).

Only one patient died of severe autoimmune hemolytic anemia and pure red cell aplasia after a booster infusion of CD34^+^ cells for poor graft function at 457 days. All 20 surviving patients were transfusion-independent. As of April 15, 2015, with a median follow-up of 35 months (range, 2 to 70 months), the estimated overall survival rate at 3 years was 94% ([Fig. 2](#F2){ref-type="fig"}). This study strongly suggests that HSCT with HFDs could be offered to children and adolescents with acquired SAA who lack suitable related or URDs. The current protocol comprised FLU, CY, r-ATG, and LD-TBI of 4 Gy with αβ-depleted grafts ([Fig. 3](#F3){ref-type="fig"}).

Future perspectives of haploidentical HSCT for SAA in pediatric patients
========================================================================

In spite of promising evidence for haploidentical HSCT in acquired SAA, there are still several obstacles to be overcome in the future for its universal use. Unresolved issues include conditioning regimen, methods to regulate the donor T-cells, stem cell source, donor selection, and management of GF or poor graft function. Future clinical trials with larger numbers of patients will help to establish the best conditioning regimen and the optimal regulation of donor T-cells leading to maximized outcomes of this novel approach. After all, the major causes of treatment failure after haploidentical HSCT for SAA are GF, including GR, severe GVHD, and infections. GF and GR are life-threatening complications after allogeneic HSCT and are more common in nonmalignant diseases including SAA, especially heavily transfused cases, than in acute leukemia[@B39][@B40]. The management of GF, especially that occurring in early posttransplantation, is often challenging. Although a second haploidentical HSCT with successful rescue has been reported, GF is a frustrating situation and therefore it is desirable to minimize the rate of GF[@B15][@B41]. Delayed immune reconstitution and subsequent infection are not uncommon and are major causes of death after haploidentical transplant. New depletion techniques or adoptive transfer of immune effector cells could enhance the recovery of immune functions after haploidentical HSCT[@B42][@B43]. Our experience with αβ^+^ T-cell-depleted haploidentical transplants, presented at the annual winter meeting of the Korean Society of Blood and Marrow Transplantation in 2014, showed faster immune recovery compared with CD3-depleted transplants.

Conclusion
==========

Currently, substantial progress in haploidentical HSCT has been achieved for the treatment of patients with both nonmalignant diseases, including SAA, and malignant diseases. Haploidentical transplant could provide a chance to save the lives and restore the normal lifestyles of pediatric patients with SAA in need of frequent transfusions and repeated antibiotic therapy to maintain their lives.

Further improvements to decrease the rates of GF, GVHD, and infectious complications as well as to appropriately deal with poor graft function will facilitate the emergence of haploidentical HSCT as a front-line therapy for treating acquired SAA in children and adolescents who have no suitably matched donors.
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###### Advantages of haploidentical hematopoietic stem cell transplantation
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  --------------------------------------
  Availability for almost all patients
  Immediate donor accessibility
  No racial or ethnic restrictions
  Multiple donors
  Continued donor access
  --------------------------------------

###### Approaches in T-cell depletion for haploidentical hematopoietic stem cell transplantation
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  --------------------------------------
  *Ex vivo* T-cell depletion
   Indirect T-cell depletion
    Selection of CD34^+^ cells
   Direct T-cell depletion
    Depletion of CD3^+^ T cells
    Depletion of αβ^+^ T cells
  *In vivo* T-cell depletion
   Antilymphocyte antibodies
   Allodepletion with cyclophosphamide
  --------------------------------------

###### Haploidentical hematopoietic stem cell transplantation in acquired severe aplastic anemia
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  Source                       No.   Age at HSCT (yr), median (range)   Conditioning regimen   *Ex vivo* T-cell depletion   Primary GF, n (%)   GVHD, n (%)   Death (n)   Cause of death (n)   Survival           
  ---------------------------- ----- ---------------------------------- ---------------------- ---------------------------- ------------------- ------------- ----------- -------------------- ---------- --- --- --------------
  Xu et al.[@B33] (2012)       19    19 (5-33)                          BU, CY, ATG            No                           0 (0)               8 (42)        9 (56)      6                    2          2   2   65% at 2 yr
  Im et al.[@B34] (2013)       12    13 (3-21)                          FLU, CY, ATG±TBI       Yes                          1 (8.3)             3 (33)        2 (22)      0                    0          0   0   100% at 1 yr
  Gao et al.[@B35] (2014)      26    25 (18-41)                         FLU, CY, ATG           No                           1 (3.8)             3 (12)        10 (40)     4                    2          1   1   85% at 3 yr
  Wang et al.[@B36] (2014)     17    10 (4-19)                          BU, FLU, CY, ATG       No                           0 (0)               5 (29)        4 (27)      3                    0          1   2   72% at 1 yr
  Clay et al.[@B37] (2014)     8     32 (19-57)                         FLU, CY, TBI           No                           2 (25)              1 (13)        0 (0)       2                    2          0   0   75% at 1 yr
  Steves et al.[@B38] (2015)   16    17 (5-39)                          FLU, CY, TBI           No                           1 (6)               2 (13)        3 (20)      5                    0          0   5   67% at 1 yr
  Current study                21    14 (3-21)                          FLU, CY, ATG±TBI       Yes                          1 (4.8)             6 (30)        2 (10)      1                    1^\*^      0   0   94% at 3 yr

HSCT, hematopoietic stem cell transplantation; GF, graft failure; GVHD, graft-versus-host disease; BU, busulfan; CY, cyclophosphamide; ATG, antithymocyte globulin; FLU, fludarabine; TBI, total body irradiation.

^\*^The patient died of complications after a booster infusion of CD34^+^ cells for poor graft function.
